Compare PMN & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PMN | UNCY |
|---|---|---|
| Founded | 2004 | 2016 |
| Country | Canada | United States |
| Employees | N/A | 22 |
| Industry | Pharmaceuticals and Biotechnology | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.5M | 126.4M |
| IPO Year | N/A | 2021 |
| Metric | PMN | UNCY |
|---|---|---|
| Price | $9.01 | $5.45 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $72.67 | $44.50 |
| AVG Volume (30 Days) | 43.4K | ★ 350.7K |
| Earning Date | 11-12-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.27 | $3.71 |
| 52 Week High | $39.75 | $11.00 |
| Indicator | PMN | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | 83.68 | 44.20 |
| Support Level | $7.35 | $6.31 |
| Resistance Level | $9.42 | $6.95 |
| Average True Range (ATR) | 0.68 | 0.41 |
| MACD | 0.18 | -0.12 |
| Stochastic Oscillator | 86.35 | 4.26 |
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.